Cancer Research and Treatment

Volume 40(2); June 2008

Original Articles

Differential Physiological Effects of Raf-1 Kinase Pathways Linked to Protein Kinase C Activation Depending on the Stimulus in v-H-ras-transformed Cells: Michael Lee; Cancer Res Treat. 2008;40(2):39-44. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.39

Purpose

We investigated the molecular mechanism by which the Raf-1 kinase pathways that are linked to protein kinase C induce differential physiological effects, depending on the stimulus, by employing the pharmacological PKC activator PMA.

Materials and Methods

Parental and v-Ha-ras transfected NIH 3T3 cells were chosen as test systems and these cells were transiently transfected with the pMTH vector that encodes dominant-negative (DN) PKC-ε with using Lipofectamine 2000. The cell proliferation reagent WST-1 was used for the quantitative determination of cellular proliferation. The Raf-1 kinase activity was measured by assessing the phosphorylation of recombinant MEK with using the immunoprecipitated Raf-1 proteins. The phosphorylated MEK protein bands were quantified by using Quantity One analysis software.

Results

The pharmacological PKC activator phorbol-12-myristate-13-acetate (PMA) and platelet-derived growth factor (PDGF) were able to induce the activation of Raf-1 kinase in the v-H-ras-transformed NIH3T3 fibroblasts. However, PMA was found to be much less sensitive PI3 kinase inhibitor or the chemical antioxidant than is PDGF. Especially, PMA mediated growth arrest while PDGF induced mitogenic signaling through the PKC-ε activation. Thus, the regulation of the Raf-1 cascade by both PDGF and PMA is likely to be intimately linked and they converge at the PKC level through different upstream pathways, as was shown by the inhibition of PDGF-induced Raf-1 kinase activation by the transient transfection with a dominant-negative mutant of PKC-ε.

Conclusions

Taken together, these results imply that, depending on the stimulus, Raf-1 kinase leads to different physiological effects.

Citations

Citations to this article as recorded by

Study of the correlation between H-ras mutation and primary hepatocellular carcinoma
GUODE SUI, XUEXIAO MA, SHIGUO LIU, HAITAO NIU, QIAN DONG
Oncology Letters.2012; 4(4): 779. CrossRef
Identification and validation of calmodulin as a binding protein of an anti‐proliferative small molecule 3,4‐dihydroisoquinolinium salt
Hye Jin Jung, Joong Sup Shim, Jungchan Park, Hyun‐Joon Ha, Jung‐Ho Kim, Joong‐Gon Kim, Nam Doo Kim, Jeong Hyeok Yoon, Ho Jeong Kwon
PROTEOMICS – Clinical Applications.2009; 3(4): 423. CrossRef

7,658 View
29 Download
2 Crossref

Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients: Na-Hye Myong; Cancer Res Treat. 2008;40(2):45-52. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.45

Abstract PDF PubReader ePub

Purpose

We investigated the immunoexpressions of cyclin D1, cyclin-dependent kinase inhibitor p16 and phosphorylated retinoblastoma (p-pRb) proteins in non-small cell lung carcinoma (NSCLC) to demonstrate their key roles in tumorigenesis, their relationship with the clinicopathologic factors, and their prognostic influences on the long-term survival.

Materials and Methods

115 surgically resected NSCLCs were immunohistochemically stained for the G₁/S cell cycle proteins, with using a tissue microarray. The correlation between their immunoexpressions and the clinicopathologic prognostic factors, their inter-relationships and their single or combined effects on the long-term survival (over 5 years) were statistically analyzed by SPSS15.0.

Results

Loss of p16 was found in 75% of the cases and cyclin D1 overexpression and phosphorylated pRb (p-pRb) were found in 64% and 46%, respectively. Cyclin D1 overexpression was correlated with the p16 loss and pRb inactivation by phosphorylation. The p16 loss was tightly associated with p-pRb. The Kaplan-Meier survival curves disclosed that the cyclin D1-positive group and the p16-negative group showed a rapid decline of survival at the point of about 5 years after surgery and thereafter. The combined actions of cyclin D1 overexpression, loss of p16 and pRb inactivation tended to have an adverse influence on the prolonged survival.

Conclusions

The observation that cyclin D1 overexpression, p16 loss and pRb inactivation were largely found in NSCLCs suggests that they play an important role in pulmonary carcinogenesis. Also, their inverse or positive correlations indicate that the G₁/S cell cycle proteins may act alternatively or synergistically on the mechanisms by which tumor cells escape the G₁ restriction point. Finally, their solitary or combined actions might have a long-term effect on the survival.

Citations

Citations to this article as recorded by

Human Papillomavirus Is Rare and Does Not Correlate with p16INK4A Expression in Non-Small-Cell Lung Cancer in a Jordanian Subpopulation
Ola Abu Al Karsaneh, Arwa Al Anber, Sahar AlMustafa, Hussien AlMa’aitah, Batool AlQadri, Abir Igbaria, Rama Tayem, Mustafa Khasawneh, Shaima Batayha, Tareq Saleh, Mohammad ALQudah, Maher Sughayer
Medicina.2024; 60(4): 660. CrossRef
RB1: governor of the cell cycle in health and disease—a primer for the practising pathologist
Fleur Cordier, David Creytens
Journal of Clinical Pathology.2024; 77(7): 435. CrossRef
The Intersection of Genetic and Molecular Biology in Oral Potentially Malignant Disorders: Identifying Key Biomarkers and Pathways for Clinical Intervention
Hema Shree K
International Journal of Histopathological Interpretation.2024; 13(2): 1. CrossRef
Effects of the p16/cyclin D1/CDK4/Rb/E2F1 pathway on aberrant lung fibroblast proliferation in neonatal rats exposed to hyperoxia
Shimeng Zhao, Zhiguang Chen, Shuang Han, Hongmin Wu
Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators
Chih-Yi Liu, Ching-Shui Huang, Chi-Cheng Huang, Wei-Chi Ku, Hsing-Yu Shih, Chi-Jung Huang
Cancers.2021; 13(21): 5486. CrossRef
Ultrasound-Targeted Microbubble Destruction Mediated si-CyclinD1 Inhibits the Development of Hepatocellular Carcinoma via Suppression of PI3K/AKT Signaling Pathway

Wei Yan, Li Cheng, Dongmei Zhang
Cancer Management and Research.2020; Volume 12: 10829. CrossRef
Loss of pRB in Conjunctival Squamous Cell Carcinoma: A Predictor of Poor Prognosis
Sheetal Chauhan, Seema Sen, Anjana Sharma, Seema Kashyap, Radhika Tandon, Neelam Pushker, Murugesan Vanathi, Shyam S. Chauhan
Applied Immunohistochemistry & Molecular Morphology.2018; 26(6): e70. CrossRef
Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways
Vítor Sousa, Bruno Bastos, Maria Silva, Ana Maria Alarcão, Lina Carvalho
Revista Portuguesa de Pneumologia (English Edition).2015; 21(5): 259. CrossRef
Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression
Rita Nahta, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Rafaela Andrade-Vieira, Sarah N. Bay, Dustin G. Brown, Gloria M. Calaf, Robert C. Castellino, Karine A. Cohen-Solal, Anna Maria Colacci, Nichola Cruickshanks, Paul Dent, Riccardo Di Fiore, Stefa
Carcinogenesis.2015; 36(Suppl 1): S2. CrossRef
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead
William H. Goodson, Leroy Lowe, David O. Carpenter, Michael Gilbertson, Abdul Manaf Ali, Adela Lopez de Cerain Salsamendi, Ahmed Lasfar, Amancio Carnero, Amaya Azqueta, Amedeo Amedei, Amelia K. Charles, Andrew R. Collins, Andrew Ward, Anna C. Salzberg, An
Carcinogenesis.2015; 36(Suppl 1): S254. CrossRef
Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary
George Fotopoulos, Anna Gousia, Eleni Bareta, Epameinondas Koumpis, Sofia Chrisafi, Matthaios Bobos, Vassiliki Malamou‐Mitsi, George Fountzilas, Nicholas Pavlidis, George Pentheroudakis
European Journal of Clinical Investigation.2015; 45(11): 1145. CrossRef
WITHDRAWN: Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways
Vítor Sousa, Bruno Bastos, Maria Silva, Ana Maria Alarcão, Lina Carvalho
Revista Portuguesa de Pneumologia.2014;[Epub] CrossRef
Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls
Yuan-Yuan Hu, Rong Zheng, Chong Guo, Yu-Ming Niu
Diagnostic Pathology.2014;[Epub] CrossRef
Chordoma: the entity
Youssef Yakkioui, Jacobus J. van Overbeeke, Remco Santegoeds, Manon van Engeland, Yasin Temel
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1846(2): 655. CrossRef
RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis
Riccardo Di Fiore, Antonella D'Anneo, Giovanni Tesoriere, Renza Vento
Journal of Cellular Physiology.2013; 228(8): 1676. CrossRef
Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer
William Sterlacci, Michael Fiegl, Alexandar Tzankov
Pathobiology.2012; 79(4): 175. CrossRef
Expression of Cyclin D1 Is Associated with β-Catenin Expression and Correlates with Good Prognosis in Colorectal Adenocarcinoma
Kyu Yun Jang, Yo Na Kim, Jun Sang Bae, Myoung Ja Chung, Woo Sung Moon, Myoung Jae Kang, Dong Geun Lee, Ho Sung Park
Translational Oncology.2012; 5(5): 370. CrossRef
A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas
William Sterlacci, Alexandar Tzankov, Lothar Veits, Bettina Zelger, Michel P. Bihl, Anja Foerster, Florian Augustin, Michael Fiegl, Spasenija Savic
Journal of Thoracic Oncology.2011; 6(10): 1649. CrossRef
Expression of p16 in non-small cell lung cancer and its prognostic significance: A meta-analysis of published literatures
Jinlong Tong, Xinchen Sun, Hongyan Cheng, Di Zhao, Jun Ma, Qing Zhen, Yuandong Cao, Huiping Zhu, Jianling Bai
Lung Cancer.2011; 74(2): 155. CrossRef

10,621 View
54 Download
19 Crossref

Cytoplasmic Trapping of CXCR4 in Hepatocellular Carcinoma Cell Lines: Seong-Woo Kim, Ha-Yon Kim, Ik-Chan Song, Seon-Ah Jin, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo; Cancer Res Treat. 2008;40(2):53-61. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.53

Abstract PDF PubReader ePub

Purpose

The chemokine receptor CXCR4 plays a role in the metastasis and progression of a broad range of malignant tumors; however, its influence on hepatocellular carcinoma (HCC) is not well defined. Thus, we analyzed the expression of CXCR4 and its functions in HCC cell lines in vitro.

Materials and Methods

Five HCC cell lines (HepG2, Hep3B, SK-HEP-1, NCI-H630 and PLC/PRF5) were investigated. The CXCR4 expression was analyzed by RT-PCR, Western blotting, flow cytometry and immunofluorescence staining. In addition, the effects of stromal cell-derived factor-1 (SDF-1) on the migration, proliferation and survival of the cells were investigated, as well as the SDF-1-induced phosphorylation of signaling molecules.

Results

All five cell lines had abundant CXCR4 in their cytoplasm, whereas a cell surface CXCR4 expression was only detected in a very small population of PLC/PRF5 cells. In contrast, SDF-1 bound to all the cells. SDF-1 induced the phosphorylation of AKT and ERK1/2 in the PLC/PRF5 cells and the phosphorylation of Stat3, AKT and ERK1/2 in the Hep3B cells. Nonetheless, SDF-1 did not induce migration or proliferation in any of the cells, nor did it rescue the cells from serum deprivation-induced apoptosis. Recruitment of CXCR4 from the cytoplasm to the cell surface was not elicited by dexamethasone, proinflammatory cytokines or VEGF. Hypoxia increased both the cytoplasmic and cell surface expressions of CXCR4 in only the PLC/PRF5 cells.

Conclusions

CXCR4 is trapped in the cytoplasm and it is not recruited to the cell surface by standard extrinsic stimuli in the majority of HCC cell lines, and the result of this is a negligible response to SDF-1.

Citations

Citations to this article as recorded by

CXCR4, regulated by HIF1A, promotes endometrial breakdown via CD45+ leukocyte recruitment in a mouse model of menstruation
Shufang Wang, Xihua Chen, Shige Guo, Fang Zhou, Xin Zhang, Cong Lu, Xuqing Yang, Qianxing Wang, Bin He, Jiedong Wang, Hanbi Wang, Xiangbo Xu
Reproductive Biology.2023; 23(3): 100785. CrossRef
Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells
Megan M. Harper, Miranda Lin, Michael J. Cavnar, Prakash K. Pandalai, Reema A. Patel, Mei Gao, Joseph Kim, Ming Tan
PLOS ONE.2022; 17(7): e0270832. CrossRef
The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature
Jan Korbecki, Klaudyna Kojder, Patrycja Kapczuk, Patrycja Kupnicka, Barbara Gawrońska-Szklarz, Izabela Gutowska, Dariusz Chlubek, Irena Baranowska-Bosiacka
International Journal of Molecular Sciences.2021; 22(2): 843. CrossRef
Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets
Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp
BMC Cancer.2017;[Epub] CrossRef
Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma
Kuo-Shyang Jeng, Chi-Juei Jeng, Wen-Juei Jeng, Chiung-Fang Chang, I-Shyan Sheen
Oncology Letters.2017; 14(2): 1905. CrossRef
An Ultra‐High Fluorescence Enhancement and High Throughput Assay for Revealing Expression and Internalization of Chemokine Receptor CXCR4
Hua He, Xiaojuan Wang, Tiantian Cheng, Yongqing Xia, Jun Lao, Baosheng Ge, Hao Ren, Naseer Ullah Khan, Fang Huang
Chemistry – A European Journal.2016; 22(17): 5863. CrossRef
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
Maria Neve Polimeno, Caterina Ierano, Crescenzo D'Alterio, Nunzia Simona Losito, Maria Napolitano, Luigi Portella, Giosuè Scognamiglio, Fabiana Tatangelo, Anna Maria Trotta, Steven Curley, Susan Costantini, Raffaele Liuzzi, Francesco Izzo, Stefania Scala
Cellular & Molecular Immunology.2015; 12(4): 474. CrossRef
Mechanisms regulating cell membrane localization of the chemokine receptor CXCR4 in human hepatocarcinoma cells
Edgar B. Cepeda, Tatjana Dediulia, Joan Fernando, Esther Bertran, Gustavo Egea, Estanislao Navarro, Isabel Fabregat
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2015; 1853(5): 1205. CrossRef
Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance
Marina Okuyama Kishima, Carlos Eduardo Coral de Oliveira, Bruna Karina Banin-Hirata, Roberta Losi-Guembarovski, Karen Brajão de Oliveira, Marla Karine Amarante, Maria Angelica Ehara Watanabe
Analytical Cellular Pathology.2015; 2015: 1. CrossRef
Intracellular coexpression of CXC- and CC– chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation
Sandra Pinto, Alicia Martínez-Romero, José-Enrique O’Connor, Rosario Gil-Benso, Teresa San-Miguel, Liria Terrádez, Carlos Monteagudo, Robert C Callaghan
BMC Cancer.2014;[Epub] CrossRef
Intracellular trafficking and endocytosis of CXCR4 in fetal mesenchymal stem/stromal cells
Rebecca A Pelekanos, Michael J Ting, Varda S Sardesai, Jennifer M Ryan, Yaw-Chyn Lim, Jerry KY Chan, Nicholas M Fisk
BMC Cell Biology.2014;[Epub] CrossRef
Downregulation of the proangiogenic prostaglandin E receptor EP3 and reduced angiogenesis in a mouse model of diabetes mellitus
Kazuhito Oba, Kanako Hosono, Hideki Amano, Shin-ichiro Okizaki, Yoshiya Ito, Masayoshi Shichiri, Masataka Majima
Biomedicine & Pharmacotherapy.2014; 68(8): 1125. CrossRef
Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF-1α expression in vivo
HUAQI ZHU, QIMAN SUN, CHANGJUN TAN, MIN XU, ZHI DAI, ZHENG WANG, JIA FAN, JIAN ZHOU
Molecular Medicine Reports.2014; 10(2): 585. CrossRef
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration
Caterina Ierano, Agnes Basseville, Kenneth K.W. To, Zhirong Zhan, Robert W. Robey, Julia Wilkerson, Susan E. Bates, Stefania Scala
Cancer Biology & Therapy.2013; 14(2): 175. CrossRef

11,643 View
60 Download
14 Crossref

Treatment Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer: Tae Hee Kim, Yoon Ho Ko, Myung Ah Lee, Bum-soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Min Sik Kim, Dong-Il Sun, Young Seon Hong, Kyung Shik Lee, Jin-Hyoung Kang; Cancer Res Treat. 2008;40(2):62-70. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.62

Abstract PDF PubReader ePub

Purpose

The standard treatment of locally advanced nasopharyngeal cancer is a concurrent chemoradiotherapy (CCRT), and cisplatin has been used as the most popular chemotherapeutic agent. But many different doses and schedules for cisplatin administration such as daily, weekly and 3 week cycles have been proposed. We compared and analyzed the tumor response, the overall survival, the toxicity and the chemotherapy dose intensity in the patients with locally advanced nasopharyngeal cancer who were treated with CCRT.

Materials and Methods

We performed a retrospective study on 55 patients with locally advanced nasopharyngeal cancer, and they were treated with CCRT as a front-line treatment from Jan 1996 to Jun 2007 at Kangnam Saint Mary's Hospital.

Results

The patients had a median age of 53 years (range: 19~75 years). Of the total 55 patients, a 3-week cycle of 100mg cisplatin was administered in 31 patients and 30 mg weekly cisplatin was administered in 24 patients combined with radiotherapy. Twenty one patients had a complete response and four patients had a partial response for a response rate of 71.4% (95% CI: 59.5~83.3) after CCRT and followed by adjuvant chemotherapy. The complete response rates for the 30 mg and 100 mg cisplatin groups were 72.7% (95% CI: 54.9~90.5) and 54.2% (95% CI: 36.7~71.7), respectively (p=0.23). The duration of CCRT in the 100mg cisplatin group was significantly longer than that of the 30mg cisplatin group (11.1±2.9 weeks vs. 9.0±1.2 weeks, p=0.003). The major deviation group, which was defined as prolongation of the radiotherapy duration for more than 2 weeks, had a significantly lower objective response rate than did the non-deviation group (56.3% vs 84.2%, respectively, p=0.002). The major severe toxicities were leucopenia (49.1%), pharyngoesophagitis (49.1%), anorexia (43.6%), nausea (41.8%) and vomiting (40%).

Conclusions

Weekly 30mg cisplatin-based CCRT is a practical, feasible cisplatin schedule for the patients with locally advanced nasopharyngeal cancer in regard to decreasing the interruption of radiation treatment and decreasing the treatment-related acute toxicities.

Citations

Citations to this article as recorded by

A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
Radiotherapy and Oncology.2025; 203: 110660. CrossRef
The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort
S. Ghosh-Laskar, A. Pilar, K. Prabhash, A. Joshi, J.P. Agarwal, T. Gupta, A. Budrukkar, V. Murthy, M. Swain, V. Noronha, V.M. Patil, P. Pai, D. Nair, D.A. Chaukar, S. Thiagarajan, G. Pantvaidya, A. Deshmukh, P. Chaturvedi, S. Nair, A. D‘Cruz
Clinical Oncology.2019; 31(12): 850. CrossRef
Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie
Tumor Biology.2016; 37(4): 4429. CrossRef
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
Cheng-run Du, Hong-mei Ying, Fang-fang Kong, Rui-ping Zhai, Chao-su Hu
Radiation Oncology.2015;[Epub] CrossRef
Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
Cai-neng Cao, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu, Riccardo Dolcetti
PLOS ONE.2015; 10(3): e0119101. CrossRef
Controversies in the systemic treatment of Nasopharyngeal carcinoma
Herbert H. Loong, Anthony T.C. Chan
Oral Oncology.2014; 50(9): 785. CrossRef
Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao, Guozhen Xu
Radiation Oncology.2014;[Epub] CrossRef
Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis
Po-Chun Chen, Ching-Chieh Yang, Cheng-Jung Wu, Wen-Shan Liu, Wei-Lun Huang, Ching-Chih Lee, Bart O. Williams
PLoS ONE.2014; 9(10): e109930. CrossRef
Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area
Weihong Wei, Zeli Huang, Shaoen Li, Hemei Chen, Guoyi Zhang, Shuxia Li, Weihan Hu, Tao Xu
Oncology Research and Treatment.2014; 37(3): 88. CrossRef
Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Qiu-Yan Chen, Yue-Feng Wen, Ling Guo, Huai Liu, Pei-Yu Huang, Hao-Yuan Mo, Ning-Wei Li, Yan-Qun Xiang, Dong-Hua Luo, Fang Qiu, Rui Sun, Man-Quan Deng, Ming-Yuan Chen, Yi-Jun Hua, Xiang Guo, Ka-Jia Cao, Ming-Huang Hong, Chao-Nan Qian, Hai-Qiang Mai
JNCI: Journal of the National Cancer Institute.2011; 103(23): 1761. CrossRef
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Research and Treatment.2008; 40(4): 155. CrossRef

12,589 View
70 Download
12 Crossref

Clinical Characteristics of Multiple Primary Colorectal Cancers: Joo Won Yoon, Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek; Cancer Res Treat. 2008;40(2):71-74. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.71

Abstract PDF PubReader ePub

Purpose

Although multiple primary colorectal cancer has been recognized as a significant clinical entity, its clinical and pathological features and its prognosis are still controversial. The purpose of this study was to clarify clinical and pathological features of multiple primary colorectal cancer.

Materials and Methods

Among 1669 patients who underwent surgery for primary colorectal cancer from January 1997 to June 2005, 26 patients (1.6%) with multiple primary colorectal cancer were identified. We reviewed clinical characteristics including diagnostic interval, lesions, operating methods, and TNM stage, and we defined the index lesion as the most advanced lesion among the synchronous lesions. For the purposes of the study, the colon and rectum were classified into three segments. The right-side colon included the appendix, cecum, ascending colon, hepatic flexure, and transverse colon, and the left-side colon included the splenic flexure, descending colon, and sigmoid colon.

Results

Of the 26 patients with multiple primary colorectal cancers, nineteen patients were male and seven patients were female, with a mean age of 61.5 years. Nineteen patients had synchronous colorectal cancers and seven patients had metachronous colorectal cancers. In the metachronous cases, the mean diagnostic interval was 36.8 months. The site of the first lesion in metachronous colorectal cancers was the right colon in five cases (71.4%) and the left colon in two cases (28.6%), and the site of the second lesion was the rectum in six cases (55.5%), the right colon in three cases (33.3%), and the left colon in one case. The TNM stage of the second lesions in the metachronous colorectal cancers was stage II in four cases (57.1%), stage III in one case (14.3%), and stage IV in one case (14.3%). For the synchronous colorectal cancers, the operation methods were single-segment resection combined with endoscopic mucosal resection in five cases (26.3%), single-segment resection alone in six cases, two-segment resection in six cases, and total colectomy in two cases.

Conclusion

In metachronous colorectal cancers, the secondary lesions were later-stage cancer. Therefore, careful postoperative follow-up is necessary for patients who have undergone surgery for colorectal cancers. Further study of therapeutic modalities is important for synchronous colorectal cancers.

Citations

Citations to this article as recorded by

A nomogram for predicting the overall survival in rectal cancer patients after total neoadjuvant therapy
Z. Liu, M. He, X. Wang
Techniques in Coloproctology.2024;[Epub] CrossRef
Developing prognostic nomograms to predict overall survival and cancer-specific survival in synchronous multiple primary colorectal cancer based on the SEER database
Xiangyu Zhang, Yanpeng Hu, Kai Deng, Wanbo Ren, Jie Zhang, Cuicui Liu, Baoqing Ma
Journal of Cancer Research and Clinical Oncology.2023; 149(15): 14057. CrossRef
A Pathomimetic Colorectal Tumor‐on‐a‐Chip for In Vitro Reconstitution of the Primary Colorectal Cancer
Zhangcai Liu, Ziming Yu, Jianpei Dong, Deyu Yang, Juanhua Li, Zhen He, Jianhua Zhou, Lu Huang
Advanced Materials Technologies.2023;[Epub] CrossRef
The incidence of second primary cancer in male and female patients with initial colorectal cancer: a SEER population-based study
Yanyan Chen, Chao Han, Yadi Huang, Chao Liu, Siqi Sheng, Linlin Ji, Jialong Zhu, Gongbo Fu, Xiaobei Mao, Mengxi Huang, Zengjie Lei, Xiaoyuan Chu
European Journal of Cancer Prevention.2022; 31(5): 430. CrossRef
Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing
Ellie S. Hong, Wells A. Messersmith, Hazem Hammad, Toby C. Cornish, Dara L. Aisner
JCO Precision Oncology.2022;[Epub] CrossRef
Do Patients with Second Primary Colorectal Cancer Hold the Similar Prognosis and Therapeutic Benefits as Those with Initial Primary Colorectal Cancer?
Quan Chen, Shan Zhao, Yongxi Song, Peng Gao, Jingxu Sun, Xiaowan Chen, Yu Sun, Zhenning Wang
BioMed Research International.2018; 2018: 1. CrossRef
KRASmutation status impacts diagnosis and treatment decision in a patient with two colon tumours: a case report
Xiaodong Li, G Pezeshkpour, Ryan T Phan
Journal of Clinical Pathology.2015; 68(1): 83. CrossRef
Two Synchronous Colonic Adenocarcinomas, a Gastric Schwannoma and a Mucinous Neoplasm of the Appendix: a Case Report
Diogo Sousa, Miguel Allen, Alda Pinto, Andreia Ferreira, Ana Cruz, Diogo Marinho, Pierpaolo Cusati, José Augusto Martins
Journal of Gastrointestinal Cancer.2015; 46(3): 304. CrossRef
KRAS and BRAF genotyping of synchronous colorectal carcinomas
RICCARDO GIANNINI, CRISTIANA LUPI, FOTIOS LOUPAKIS, ADELE SERVADIO, CHIARA CREMOLINI, ELISA SENSI, MASSIMO CHIARUGI, CARLOTTA ANTONIOTTI, FULVIO BASOLO, ALFREDO FALCONE, GABRIELLA FONTANINI
Oncology Letters.2014; 7(5): 1532. CrossRef
Population-based data from the Swedish Colon Cancer Registry
K Kodeda, L Nathanaelsson, B Jung, H Olsson, P Jestin, A Sjövall, B Glimelius, L Påhlman, I Syk
British Journal of Surgery.2013; 100(8): 1100. CrossRef
Metachronous carcinomas in colorectum and its clinicopathological significance
Alfred King-Yin Lam, Vinod Gopalan, Robert Carmichael, Petra Gertraud Buettner, Melissa Leung, Robert Smith, Cu-Tai Lu, Yik-Hong Ho, Simon Siu
International Journal of Colorectal Disease.2012; 27(10): 1303. CrossRef
Metastasis at the Colostomy Site: A Rare Case Report
Y.-H. Kuo, C.-C. Chin, K.-F. Lee
Japanese Journal of Clinical Oncology.2012; 42(8): 753. CrossRef
Total colectomy as part of primary cytoreductive surgery in advanced Müllerian cancer
Yong Jung Song, Myong Cheol Lim, Sokbom Kang, Sang-Soo Seo, Ji Won Park, Hyo Seong Choi, Sang-Yoon Park
Gynecologic Oncology.2009; 114(2): 183. CrossRef

10,005 View
63 Download
13 Crossref

Clinical Significance of Lymph Node Micrometastasis in Stage I and II Colon Cancer: Sun Jin Park, Kil Yeon Lee, Si Young Kim; Cancer Res Treat. 2008;40(2):75-80. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.75

Abstract PDF PubReader ePub

Purpose

A 25% rate of recurrence after performing complete resection in node-negative colon cancer patients suggests that their nodal staging is frequently suboptimal. Moreover, the value of occult cancer cells in tumor-free lymph nodes still remains uncertain. The authors evaluated the prognostic significance of the pathologic parameters, including the lymph node occult disease (micrometastases) detected by immunohistochemistry, in patients with node-negative colon cancer.

Materials and Methods

The study included 160 patients with curatively resected stage I or II colon cancer and they were without rectal cancer. 2852 lymph nodes were re-examined by re-do hematoxylin and eosin (H-E) staining and immunohistochemical staining. The detection rates were compared with the clinicopathologic characteristics and with the cancer-specific survival.

Results

Occult metastases were detected in 8 patients (5%). However, no clinicopathologic parameter was found to be correlated with the presence of micrometastasis. Twenty patients developed recurrence at a median follow-up of 45.7 months: 14 died of colon cancer and 9 died from noncancer-related causes. Univariate analysis showed that lymphatic invasion and the number of retrieved lymph nodes significantly influenced survival, and multivariate analysis revealed that the stage, the number of retrieved lymph nodes and lymphatic invasion were independently related to the prognosis.

Conclusions

Inadequate lymph node retrieval and lymphatic invasion were found to be associated with a poorer outcome for node-negative colon cancer patients. The presence of immunostained tumors cells in pN0 lymph nodes was found to have no significant effect on survival, but these tumor were identified by re-do H-E staining. Maximal attention should be paid to the total number of lymph nodes that are retrieved during surgery for colon cancer patients.

Citations

Citations to this article as recorded by

In comparison with polypectomy, colorectal resection is associated with improved survival for patients diagnosed with malignant polyps
Andrew P. Zammit, John D. Hooper, Ian Brown, David A. Clark, Andrew D. Riddell
Colorectal Disease.2023; 25(2): 261. CrossRef
Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection
Francesco Crafa, Serafino Vanella, Onofrio A Catalano, Kelsey L Pomykala, Mario Baiamonte
World Journal of Gastroenterology.2022; 28(30): 4019. CrossRef
Feasibility of Pooled One-Step Nucleic Acid Amplification for Molecular Staging of Pathologically Node-Negative Colon Cancer: A Prospective Multicenter Study
Kimitaka Tani, Michio Itabashi, Koichi Okuya, Kenji Okita, Ichiro Takemasa, Naohiro Tomita, Shimpei Ogawa, Yoji Nagashima, Masakazu Yamamoto
Annals of Surgical Oncology.2021; 28(13): 8804. CrossRef
Prognostic value of radiologically enlarged lymph nodes in node‐negative colon cancer
W. Song, Z. Chen, Z. Zheng, J. Hu, Y. Chen, W. Deng, X. He, P. Lan
Colorectal Disease.2020; 22(5): 537. CrossRef
Short-term outcomes of a multicentre randomized clinical trial comparing D2 versus D3 lymph node dissection for colonic cancer (COLD trial)
A Karachun, L Panaiotti, I Chernikovskiy, S Achkasov, Y Gevorkyan, N Savanovich, G Sharygin, L Markushin, O Sushkov, D Aleshin, D Shakhmatov, I Nazarov, I Muratov, O Maynovskaya, A Olkina, T Lankov, T Ovchinnikova, D Kharagezov, D Kaymakchi, A Milakin, A
Journal of British Surgery.2020; 107(5): 499. CrossRef
Which Patients with Isolated Para-aortic Lymph Node Metastasis Will Truly Benefit from Extended Lymph Node Dissection for Colon Cancer?
Sung Uk Bae, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim
Cancer Research and Treatment.2018; 50(3): 712. CrossRef
Lymph Node Micrometastasis Cannot be Considered as Positive Lymph Node in Nonmetastatic Colorectal Cancer
Kwang Dae Hong, Jun Won Um, Byung Wook Min, Woong-Bae Ji, Jung-Woo Choi, Young-Sik Kim
The American Surgeon™.2017; 83(2): 127. CrossRef
Lymph node micrometastasis in stage I and II rectal cancer
Hye-Yoon Choi, Kil Yeon Lee, Su Youn Lee, Youn Wha Kim
Korean Journal of Clinical Oncology.2016; 12(2): 110. CrossRef
Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature
Camilla Böckelman, Bodil E. Engelmann, Tuomas Kaprio, Torben F. Hansen, Bengt Glimelius
Acta Oncologica.2015; 54(1): 5. CrossRef
Targeted lymph node assessment in gastrointestinal neoplasms
Victoria O'Connor, Yuko Kitagawa, Alexander Stojadinovic, Anton J. Bilchik
Current Problems in Surgery.2014; 51(1): 9. CrossRef
The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon Cancer Patients
F. J. Vogelaar, M. S. Reimers, R. L. A. van der Linden, J. C. van der Linden, V. T. H. B. M. Smit, D. J. Lips, C. J. H. van de Velde, K. Bosscha
Annals of Surgical Oncology.2014; 21(12): 3924. CrossRef
Comparative Analysis between Multilevel Sectioning with Conventional Haematoxylin and Eosin Staining and Immunohistochemistry for Detecting Nodal Micrometastases with Stage I and II Colorectal Cancers
Yin-Ping Wong, Shamsul Azhar Shah, Noorsajida Shaari, Mohd Shafbari Mohamad Esa, Ismail Sagap, Nurismah Md Isa
Asian Pacific Journal of Cancer Prevention.2014; 15(4): 1725. CrossRef
Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy
Thilo Sprenger, Hilka Rothe, Heinz Becker, Tim Beissbarth, Kia Homayounfar, Korbinian Gauss, Julia Kitz, Hendrik Wolff, Andreas H. Scheel, Michael Ghadimi, Claus Rödel, Lena-Christin Conradi, Torsten Liersch
American Journal of Surgical Pathology.2013; 37(8): 1283. CrossRef
Lymph node micrometastasis in gastrointestinal tract cancer—a clinical aspect
Shoji Natsugoe, Takaaki Arigami, Yoshikazu Uenosono, Shigehiro Yanagita, Akihiro Nakajo, Masataka Matsumoto, Hiroshi Okumura, Yuko Kijima, Masahiko Sakoda, Yuko Mataki, Yasuto Uchikado, Shinichiro Mori, Kosei Maemura, Sumiya Ishigami
International Journal of Clinical Oncology.2013; 18(5): 752. CrossRef
Prognostic significance of histologically detected lymph node micrometastases of sizes between 0.2 and 2 mm in colorectal cancer
Bruno Märkl, C. Herbst, C. Cacchi, T. Schaller, I. Krammer, G. Schenkirsch, A. Probst, H. Spatz
International Journal of Colorectal Disease.2013; 28(7): 977. CrossRef
Prognostic significance of isolated tumor cells in patients with colorectal cancer in recent 10-year studies
YOSHITO AKAGI, TETSUSHI KINUGASA, YOSUKE ADACHI, KAZUO SHIROUZU
Molecular and Clinical Oncology.2013; 1(4): 582. CrossRef
Molecular investigation of lymph nodes in colon cancer patients using one‐step nucleic acid amplification (OSNA)
Ulrich Güller, Andreas Zettl, Mathias Worni, Igor Langer, Daniela Cabalzar‐Wondberg, Carsten T. Viehl, Nicolas Demartines, Markus Zuber
Cancer.2012; 118(24): 6039. CrossRef
Isolated Tumor Cells in Regional Lymph Nodes as Relapse Predictors in Stage I and II Colorectal Cancer
Claudia Mescoli, Laura Albertoni, Salvatore Pucciarelli, Luciano Giacomelli, Valentina M. Russo, Matteo Fassan, Donato Nitti, Massimo Rugge
Journal of Clinical Oncology.2012; 30(9): 965. CrossRef
Molecular Detection of Tumor Cells in Regional Lymph Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative Colorectal Cancer: A Systematic Review and Meta-Analysis
Nuh N. Rahbari, Ulrich Bork, Edith Motschall, Kristian Thorlund, Markus W. Büchler, Moritz Koch, Jürgen Weitz
Journal of Clinical Oncology.2012; 30(1): 60. CrossRef
Perspectives on Current Tumor-Node-Metastasis (TNM) Staging of Cancers of the Colon and Rectum
Huankai Hu, Alyssa Krasinskas, Joseph Willis
Seminars in Oncology.2011; 38(4): 500. CrossRef
Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: A veterans' affairs central cancer registry (VACCR) database analysis
Wilson I Gonsalves, Swapna Kanuri, Tsewang Tashi, Ibrahim Aldoss, Ashwin Sama, Islam Al‐Howaidi, Ashwin Ganta, Mudappa Kalaiah, Ramya Thota, Jairam Krishnamurthy, Xiang Fang, Peter Townley, Apar K. Ganti, Shanmuga Subbiah, Peter T. Silberstein
Journal of Surgical Oncology.2011; 104(6): 667. CrossRef
Impact on Prognosis of Lymph Node Micrometastasis and Isolated Tumor Cells in Stage II Colorectal Cancer
Tai Young Oh, Sun Mi Moon, Ui Sup Shin, Hyang Ran Lee, Sun Hoo Park
Journal of the Korean Society of Coloproctology.2011; 27(2): 71. CrossRef
Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients
Stanley P.L. Leong, Markus Zuber, Robert L. Ferris, Yuko Kitagawa, Ramon Cabanas, Charles Levenback, Mark Faries, Sukamal Saha
Journal of Surgical Oncology.2011; 103(6): 518. CrossRef
Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer
Arne E. Faerden, Ole H. Sjo, Ida R. K. Bukholm, Solveig Norheim Andersen, Aud Svindland, Arild Nesbakken, Arne Bakka
Diseases of the Colon & Rectum.2011; 54(2): 200. CrossRef
Detection and prognostic impact of micrometastasis in colorectal cancer
Saad Sirop, Mohammed Kanaan, Alpesh Korant, David Wiese, David Eilender, Sunil Nagpal, Madan Arora, Trevor Singh, Sukamal Saha
Journal of Surgical Oncology.2011; 103(6): 534. CrossRef
A mathematical approach to the optimal examination of lymph nodes
CHI YOUNG AHN, SE HOON KIM, SEON JUNG JANG, SOON WON HONG, HYUNKI KIM, BEOM JIN LIM
APMIS.2011; 119(12): 868. CrossRef
Cytokeratin staining for complete remission in rectal cancer after chemoradiation
Hae Ran Yun, Hee Cheol Kim, Seok Hyung Kim, Seong Hyeon Yun, Woo Yong Lee, Yong Beom Cho, Hee Jeong Shin, Ho-Kyung Chun
International Journal of Colorectal Disease.2010; 25(7): 805. CrossRef

11,907 View
96 Download
27 Crossref

Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer: Hye Jin Kim, Jin-Soo Kim, Myung-Deok Seo, So-Yeon Oh, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang; Cancer Res Treat. 2008;40(2):81-86. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.81

Abstract PDF PubReader ePub

Purpose

Anthracycline and taxanes are effective agents in advanced breast cancer and prolong survival times. Some patients achieve prolongation of life with capecitabine, gemcitabine, or vinorelbine, even after failure of both anthracycline and taxanes. We analyzed the efficacy and toxicity of gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.

Materials and Methods

The medical records of anthracycline- and taxane-pretreated metastatic breast cancer patients who received gemcitabine and vinorelbine combination chemotherapy at the Seoul National University Hospital were reviewed. Gemcitabine (1,000 mg/m²) and vinorelbine (25 mg/m²) were administered intravenously on days 1 and 8 every 3 weeks.

Results

Between 2000 and 2006, 57 patients were eligible (median age, 45 years), and the median number of previous chemotherapy regimens was 3 (range, 1~5). The overall response rate was 30% (95% CI, 18.1~41.9), and the disease control rate was 46% (PR, 30%; SD, 16%). The median duration of follow-up was 33.4 months, the median time-to-progression (TTP) was 3.9 months, and the median overall survival was 10.8 months. None of thepatients with patients with anthracycline and taxane primary resistance showed a response and the median TTP for these patients was significantly shorter than that of other patients (1.9 vs. 4.4 months; p=0.018). Although the efficacy was unsatisfactory in patients with both anthracycline and taxane primary resistance, gemcitabine and vinorelbine combination chemotherapy showed comparable efficacy in anthracycline- and/or taxane-sensitive patients and the patients with secondary resistance, even after failure of second-line therapy. Grade 3/4 hematologic toxicities included neutropenia (18.1%) and febrile neutropenia (0.3%), and non-hematologic toxicities were tolerable.

Conclusion

Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer was effective and tolerable.

Citations

Citations to this article as recorded by

Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015
Jun Yamamura, Norikazu Masuda, Daigo Yamamoto, Shigeru Tsuyuki, Masahide Yamaguchi, Satoru Tanaka, Junji Tsurutani, Shinya Tokunaga, Katsuhide Yoshidome, Makiko Mizutani, Toyokazu Aono, Asako Ooe, Hirokazu Tanino, Nobuki Matsunami, Hiroyuki Yasojima, Taka
Chemotherapy.2017; 62(5): 307. CrossRef
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10
Sook Hee Hong, Soohyeon Lee, Hoon-Gu Kim, Hyo Jin Lee, Kyung Hae Jung, Sang-Cheol Lee, Na-Ri Lee, Jina Yun, In Sook Woo, Kyong Hwa Park, Kyoung-ha Kim, Ho Young Kim, Sun Young Rha, Jae Ho Byun
Gynecologic Oncology.2015; 136(2): 212. CrossRef
‘Who’, ‘when’ and ‘how’ in re-irradiation of recurrent painful bone metastases
Florence Mok, Kenneth Li, Rebecca Yeung, Kam-Hung Wong, Brian Yu, Erin Wong, Gillian Bedard, Edward Chow
Journal of Bone Oncology.2013; 2(1): 33. CrossRef
Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
Ningning Dong, Mingyu Wang, Huiqing Li, Yongchun Cui, Qisen Guo
Cancer Chemotherapy and Pharmacology.2012; 69(5): 1315. CrossRef
Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients
Luiz Gustavo Oliveira Brito, Jurandyr Moreira de Andrade, Thiago Lins-Almeida, Fábio Eduardo Zola, Mariana Novaes Pinheiro, Heitor Ricardo Cosiski Marana, Daniel Guimarães Tiezzi, Fernanda Maris Peria
Medical Oncology.2012; 29(1): 33. CrossRef

11,359 View
63 Download
5 Crossref

Discrepant Views of Korean Medical Oncologists and Cancer Patients on Complementary and Alternative Medicine: Do Yeun Kim, Bong-Seog Kim, Kyung Hee Lee, Myung Ah Lee, Young Seon Hong, Sang Won Shin, Soon Nam Lee; Cancer Res Treat. 2008;40(2):87-92. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.87

Abstract PDF PubReader ePub

Purpose

This study was designed to evaluate the communication gap between Korean medical oncologists and cancer patients on complementary and alternative medicine (CAM).

Materials and Methods

Cross sectional studies utilized the responses of 59 medical oncologists and 211 patients. To understand the communication gap, perceived reasons and nondisclosure of CAM use, reactions of physicians to disclosure, and expectations for CAM were analyzed. Data were compared with use of the chi-squared test.

Results

Both medical oncologists and patients were in accord that CAM use would privde the patients with a feeling of hope. The medical oncologists believed more often than patients to attribute CAM use for control over medical care decisions, for the treatment of an incurable disease or as a nontoxic approach (p<0.05). Regarding reasons for nondisclosure, medical oncologists were more likely to think that physicians would not understand the use of CAM, discontinue treatment or disapprove of the use of CAM (p<0.0001). Patients attributed nondisclosure mainly to the lack of questioning about CAM. Medical oncologists were more likely to warn of the risks with CAM use and less likely to encourage the use of CAM than perceived by patients (p=0.01). Patients expected that CAM could cure disease, extend survival, relieve symptoms and improve the immune system or quality of life more often than medical oncologists (p<0.05).

Conclusion

Given the discrepant views of medical oncologists and patients on the use of CAM, medical oncologists should be aware of the discrepancies and attempt to resolve any differences.

Citations

Citations to this article as recorded by

Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial
Wan-Qin Chong, Maria Jannet Mogro, Asrie Arsad, Bee-Choo Tai, Soo-Chin Lee
Supportive Care in Cancer.2021; 29(7): 3689. CrossRef
Discrepant Views of Oncologists and Cancer Patients on Complementary and Alternative Medicine in a Chinese General Hospital
Geliang Yang, Huiqing Zhang, Zheng Gan, Yifu Fan, Wei Gu, Changquan Ling
Integrative Cancer Therapies.2018; 17(2): 451. CrossRef
Information and Training Needs Regarding Complementary and Alternative Medicine: A Cross-sectional Study of Cancer Care Providers in Germany
Gudrun E. Klein, Corina Guethlin
Integrative Cancer Therapies.2018; 17(2): 380. CrossRef
China’s cancer patients’ perceptions, attitudes and participation in clinical trials of complementary and alternative medicine: A multi-center cross-sectional study
Yifu Fan, Huiqing Zhang, Geliang Yang, Cheng Wu, Yuyu Guo, Changquan Ling
European Journal of Integrative Medicine.2018; 19: 115. CrossRef
National survey of China's oncologists' knowledge, attitudes, and clinical practice patterns on complementary and alternative medicine
Geliang Yang, Richard Lee, Huiqing Zhang, Wei Gu, Peiying Yang, Changquan Ling
Oncotarget.2017; 8(8): 13440. CrossRef
Expected and perceived efficacy of complementary and alternative medicine: A comparison views of patients with cancer and oncologists
Sang Hyuck Kim, Dong Wook Shin, You-Seon Nam, So Young Kim, Hyung-kook Yang, Be Long Cho, Keeho Park, Heui-Sug Jo, Chang-Yeol Yim, Sin Kam, Jong-Hyock Park
Complementary Therapies in Medicine.2016; 28: 29. CrossRef
Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers
Gyeongyeon Hong, Jennifer White, Lihong Zhong, Linda E. Carlson
Integrative Cancer Therapies.2015; 14(4): 305. CrossRef
National Survey of US Oncologists' Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by Patients With Cancer
Richard T. Lee, Andrea Barbo, Gabriel Lopez, Amal Melhem-Bertrandt, Heather Lin, Olufunmilayo I. Olopade, Farr A. Curlin
Journal of Clinical Oncology.2014; 32(36): 4095. CrossRef
Perception and attitude of Jordanian physicians towards complementary and alternative medicine (CAM) use in oncology
Amal Al-Omari, Mohammad Al-Qudimat, Amid Abu Hmaidan, Luna Zaru
Complementary Therapies in Clinical Practice.2013; 19(2): 70. CrossRef
Investigation into the Use of Complementary and Alternative Medicine and Factors Affecting Use in Korean Patients with Brain Tumors
Yong Soon Shin, Jeong A Lee, So Hyun Bae, Su Youn Lee, Min Kyeong Jang
Journal of Korean Academy of Fundamentals of Nursing.2013; 20(2): 147. CrossRef
Complementary and alternative medicine use and assessment of quality of life in Korean breast cancer patients: a descriptive study
Eunyoung Kang, Eun Joo Yang, Sun-Mi Kim, Il Yong Chung, Sang Ah Han, Do-Hoon Ku, Soek-Jin Nam, Jung-Hyun Yang, Sung-Won Kim
Supportive Care in Cancer.2012; 20(3): 461. CrossRef
Validation of the Korean Integrative Medicine Attitude Questionnaire (IMAQ)
Jung-Ha Kim, Jung-Bok Lee, Duk-Chul Lee
Korean Journal of Family Medicine.2011; 32(3): 197. CrossRef

9,719 View
55 Download
12 Crossref

Case Reports

Primary Epithelial Ovarian Carcinoma with Gastric Metastasis Mimic Gastrointestinal Stromal Tumor: Woo Dae Kang, Cheol Hong Kim, Moon Kyoung Cho, Jong Woon Kim, Ji Shin Lee, Seong Yeob Ryu, Yoon Ha Kim, Ho Sun Choi, Seok Mo Kim; Cancer Res Treat. 2008;40(2):93-96. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.93

Abstract PDF PubReader ePub

Epithelial ovarian carcinoma rarely metastasizes to the parenchyma of the stomach. A 55-years-old woman presented with epigastric pain and a feeling of fullness for one month. A subsequent contrast-enhanced CT scan demonstrated a 4.5×4 cm submucosal mass with focal ulceration in the gastric antrum, and this finding was suggestive of GIST. After gastric antrectomy, the final pathology showed metastatic gastric tumor from a primary ovarian serous carcinoma. Because epithelial ovarian carcinoma is usually spread along the peritoneal surface, stomach involvement is rare. Furthermore, transmural gastric metastasis is very rare in a patient with primary ovarian carcinoma. Until now, there has been no reported case of stomach involvement at presentation in a patient with primary ovarian carcinoma. We present here a case of ovarian carcinoma with gastric metastasis that mimicked GIST.

Citations

Citations to this article as recorded by

Asymptomatic Gastric Metastasis From Ovarian Adenocarcinoma Presented as Gastric Subepithelial Tumor: Case Report
Qiyu Yang, Aihua Li, Zeyu Lu, Shihang Tang
JGH Open.2025;[Epub] CrossRef
Ovarian serous carcinoma with stomach metastasis: a rare case report and literature review
Jia-Li Hu, Zhao-Jiao Guo, Chun Wang, Jun Yan, Hao Yang
Journal of International Medical Research.2024;[Epub] CrossRef
Gastrointestinal Stromal Tumors (GISTs) Mimicking Primary Ovarian Tumors or Metastasizing to the Ovaries: A Systematic Literature Review
Gabriele Tonni, Andrea Palicelli, Maria Bassi, Federica Torricelli, Ilaria Vacca, Lorenzo Aguzzoli, Vincenzo Mandato
Cancers.2024; 16(13): 2305. CrossRef
Solitary Gastric Metastasis from a Stage IA Serous Ovarian Carcinoma: A Case Report with Literature Review
Keishi Mizuguchi, Hiroshi Minato, Isao Yoshida, Junpei Iwadare, Kayo Kayahashi, Yuki Mitani, Kazuyoshi Watanabe
Internal Medicine.2017; 56(8): 915. CrossRef
Isolated gastric recurrence from ovarian carcinoma: A case report
QIAN LIU, QIAN-QIAN YU, HAO WU, ZHI-HONG ZHANG, REN-HUA GUO
Oncology Letters.2015; 9(3): 1173. CrossRef
Improved Survival of a Patient with Gastric and Other Multiple Metastases from Ovarian Cancer by Multimodal Treatment: A Case Report
Seonmi Hwangbo, Oh Kyoung Kwon, Ho Young Chung, Wansik Yu
Journal of Gastric Cancer.2015; 15(3): 218. CrossRef
Clinicopathological features and treatment outcomes of metastatic tumors in the stomach
Tsutomu Namikawa, Kazuhiro Hanazaki
Surgery Today.2014; 44(8): 1392. CrossRef
Gastric Metastasis from Ovarian Cancer Presenting as a Submucosal Tumor: A Case Report
Eun Young Kim, Cho Hyun Park, Eun Sun Jung, Kyo Young Song
Journal of Gastric Cancer.2014; 14(2): 138. CrossRef
Gastric perforation secondary to metastasis from ovarian cancer: Case report
Firas Obeidat, Ayman Mismar, Maha Shomaf, Mohammad Yousef, Kamil Fram
International Journal of Surgery Case Reports.2013; 4(6): 541. CrossRef
Multiple Gastric Metastases from Ovarian Carcinoma Diagnosed by Endoscopic Ultrasound with Fine Needle Aspiration
Mehmet Akce, Sharon Bihlmeyer, Andrew Catanzaro
Case Reports in Gastrointestinal Medicine.2012; 2012: 1. CrossRef
Gastric metastasis from ovarian carcinoma diagnosed by EUS-FNA biopsy and elastography
Silvia Carrara, Claudio Doglioni, Paolo Giorgio Arcidiacono, Pier Alberto Testoni
Gastrointestinal Endoscopy.2011; 74(1): 223. CrossRef

11,470 View
69 Download
11 Crossref

A Case of Multiple Intussusceptions in the Small Intestine Caused by Metastatic Renal Cell Carcinoma: Wan Kyu Eo, Gou Young Kim, Sung Il Choi; Cancer Res Treat. 2008;40(2):97-99. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.97

Abstract PDF PubReader ePub

Renal cell carcinoma (RCC) may metastasize to almost any organ, but metastasis to the small bowel is rare. Small bowel metastasis from RCC can induce obstruction or bleeding, and perforation can also be induced in rare case. Yet RCC metastasis to the small bowel is unlikely to be a direct cause of intussusceptions. A few cases of intussusceptions caused by small intestinal metastasis of RCC have been reported, but multiple small intestinal intussusceptions are extremely rare. We report here on a 47-year-old male patient who presented to the emergency room with acute abdominal pain. He had undergone radical nephrectomy 2 years previously due to left RCC. The abdominal CT scan revealed enhanced masses with the "target" sign that suggested enteric intussusceptions in the jejunum. Eight pedunculated masses within the small intestinal lumen led to intussusceptions at 30 and 150 cm distal to Treitz ligament. Three segmental resections of the small intestine and functional end to end anastomosis were done. The patient recovered uneventfully from this operation. To the best of our knowledge, this is the 1^st report of metastases from RCC that presented as synchronous intraluminal polypoid tumors, and these tumors served as the lead points for two intussusceptions in the jejunum.

Citations

Citations to this article as recorded by

Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy
Yidan Lou, Kaibo Guo, Song Zheng
Frontiers in Oncology.2023;[Epub] CrossRef
Solitary metastasis of clear cell renal cell carcinoma in the small intestine 10 years after right nephrectomy
M.D. Budurova, N.V. Vorobyov, S.I. Poluektov, V.S. Surkova, N.A. Grishin, K.A. Turupaev, M.A. Chernichenko, A.B. Ryabov
P.A. Herzen Journal of Oncology.2023; 12(6): 57. CrossRef
Metastatic disease masquerading as small intestinal tumoural masses: two case reports and literature review
Jovell Xing Yi Sim, Ilyana Huda Binte Mohamed Hussain, Wei Qiang Leow
Proceedings of Singapore Healthcare.2017; 26(4): 263. CrossRef
Severe blood loss anaemia and recurrent intussusceptions as first presentation of bowel metastatic renal cell carcinoma: A case report and review of the literature
Claudia Trojaniello, Maria Giuseppa Vitale, Biagio Trojaniello, Maria Luisa Lentini Graziano, Mariarosa Coccaro, Giacomo Cartenì, Vincenzo Montesarchio
Molecular and Clinical Oncology.2017; 7(4): 654. CrossRef
Small bowel intussusception from renal cell carcinoma metastasis: a case report and review of the literature
Gabriele Bellio, Tommaso Cipolat Mis, Gladiola Kaso, Roberto Dattola, Biagio Casagranda, Marina Bortul
Journal of Medical Case Reports.2016;[Epub] CrossRef
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review
Morena Fasano, Carminia Maria Della Corte, Giovanni Vicidomini, Valerio Scotti, Pier Francesco Rambaldi, Alfonso Fiorelli, Marina Accardo, Ferdinando De Vita, Mario Santini, Fortunato Ciardiello, Floriana Morgillo
Oncology Letters.2016; 12(6): 4505. CrossRef
Triple jejuno-jejunal intussusception due to metastatic renal cell carcinoma
A.-S. Massy Budmiger, V. Nagy, S. Hurlimann, J. Metzger
Journal of Surgical Case Reports.2015; 2015(4): rjv047. CrossRef
An obscure cause of gastrointestinal bleeding: Renal cell carcinoma metastasis to the small bowel
Robyn L. Gorski, Salah Abdel Jalil, Manver Razick, Ala' Abdel Jalil
International Journal of Surgery Case Reports.2015; 15: 130. CrossRef
Recurrent Renal Cell Carcinoma with Synchronous Tumor Growth in Azygoesophageal Recess and Duodenum: A Rare Cause of Anemia and Upper Gastrointestinal Bleeding
Vamshidhar R. Vootla, Muhammad Kashif, Masooma Niazi, Suresh K. Nayudu
Case Reports in Oncological Medicine.2015; 2015: 1. CrossRef
Atypical Multiple Ileum Metastases of Renal Cell Carcinoma
Raffaele Longo, Domenico Gattuso, Roberto Luchetti, Carlo Giannetti, Alessandro Mero, Cinzia Bernardi, Giampietro Gasparini
Journal of Gastrointestinal Cancer.2013; 44(4): 477. CrossRef
Enduring Response to Everolimus as Third-Line Therapy in a Patient With Advanced Renal Cell Carcinoma, Including Small-Bowel Metastases: Loss of FHIT but Normal VHL Gene Status
Reuben J. Broom, Imogen Caldwell, Fritha Hanning, Peter Fong, Sanjeev Deva, Paul Oei
Clinical Genitourinary Cancer.2012; 10(3): 202. CrossRef
A case of wedge resection of duodenum for massive gastrointestinal bleeding due to duodenal metastasis by renal cell carcinoma
Hongzhi Zhao, Keqiang Han, Jing Li, Ping Liang, Guohua Zuo, Yu Zhang, Hongyan Li
World Journal of Surgical Oncology.2012;[Epub] CrossRef
Malignant Pleural Mesothelioma Presenting as an Acute Surgical Abdomen due to Metastatic Jejunal Perforation
Kyoko Gocho, Kazutoshi Isobe, Kyohei Kaburaki, Yoshiko Honda, Aki Mitsuda, Yoshikiyo Akasaka, Nagato Shimada, Keigo Takagi, Sakae Homma
Internal Medicine.2010; 49(6): 597. CrossRef

10,489 View
69 Download
13 Crossref

First
Prev
Page of 1
Next
Last

Previous issues